2014
Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research 2014, 20: 5023-5031. PMID: 25107913, PMCID: PMC4523080, DOI: 10.1158/1078-0432.ccr-14-0822.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiopsyBrain NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyDacarbazineFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedRadiosurgeryTemozolomideTreatment OutcomeYoung AdultConceptsObjective response rateOverall survivalRadiotherapy schedulesMedian overall survivalPhase II studyHypofractionated Stereotactic RadiotherapyPhase II trialApparent diffusion coefficient ratioRelative cerebral blood volumeDynamic susceptibility contrast perfusion MRICerebral blood volumeNeuropsychological test scoresMedian PFSPersistent hypermetabolismAdjuvant temozolomidePrimary endpointII studyII trialPoor OSStandard dosesFDG-PETPrognostic valuePoor prognosisHistorical controlsTumor volume
2013
Bevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdema
2012
Atypical and anaplastic meningiomas treated with bevacizumab
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalVascular endothelial growth factor receptorAnaplastic meningiomasRadiographic responseMedian progression-free survivalBest radiographic responseEfficacy of bevacizumabMonths PFS rateEndothelial growth factor receptorKaplan-Meier statisticsActivity of bevacizumabEffective chemotherapeutic optionsAnti-angiogenic agentsTumor blood volumeMR perfusion studiesGrowth factor receptorPFS ratesStable diseaseBevacizumab therapyOverall survivalRANO criteriaRetrospective reviewSurgical optionsProspective studyAggressive tumors
2010
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal Of Neuro-Oncology 2010, 100: 443-447. PMID: 20440540, PMCID: PMC3246379, DOI: 10.1007/s11060-010-0200-2.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerActive brain metastasesInitiation of bevacizumabSafety of bevacizumabProgression-free survivalBrain metastasesCell lung cancerCNS metastasisOverall survivalLung cancerCentral nervous system metastasesMedian progression-free survivalAccelerated FDA approvalActive CNS metastasesParenchymal brain metastasesProgressive brain metastasesMedian overall survivalNervous system metastasesAdditional safety dataPrimary brain tumorsHigh response rateIntra-tumoral hemorrhageBevacizumab safetyConcurrent anticoagulationCorticosteroid requirements
2008
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Current Opinion In Neurology 2008, 21: 717-719. PMID: 18989118, DOI: 10.1097/wco.0b013e3283184625.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, PhytogenicBevacizumabCamptothecinGlioblastomaGliomaHumansIrinotecanConceptsMalignant gliomasOverall survivalClinical trialsProspective phase II trialPlace of bevacizumabProgression-free survivalPhase II trialNew treatment strategiesHigh response rateTreatment of glioblastomaII trialRecurrent diseaseSalvage treatmentCytotoxic chemotherapyMost patientsConventional radiographic methodsDisease progressionHistorical controlsSurvival resultsRadiographic criteriaTreatment strategiesBevacizumabResponse rateNew treatmentsGliomas